| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
Raises full-year 2026 total global revenue guidance to approximately $1 billion, from approximately $950 million |
| 03 Aug 2026 |
8-K: Results of Operations and Financial Condition
Second quarter 2026 total global revenue of approximately $240 million, including BRIUMVI U.S. net product revenue of approximately $228 million |
| 12 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On Thursday, June 11, 2026, at 9:30 a.m. Eastern Time, by means of an online meeting platform, TG Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting. Stockholders representing 113,003,414, or 73.81%, of the 153,093,879 outst... |
| 03 Jun 2026 |
8-K: Other Events
Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under evaluation in fully enrolled Phase 3 trial; Top-line Phase 3 data expected year-end 2026 or early 2027 |
| 27 May 2026 |
8-K: Other Events
Phase 3 trial met its primary endpoint, demonstrating bioequivalent drug exposure between the currently approved BRIUMVI Day 1 and Day 15 initiation dosing and a new single infusion on Day 1 only |
| 06 May 2026 |
8-K: Results of Operations and Financial Condition
First quarter 2026 total global revenue of approximately $205 million, including BRIUMVI U.S. net revenue of approximately $195 million |
| 20 Mar 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
On March 18, 2026 (the “Closing Date”), the Company (the “Borrower”) entered into the first amendment agreement, dated as of the Closing Date (the “First Amendment”), by and among the Borrower, certain subsidiaries of the Borrower, as gu... |
| 26 Feb 2026 |
8-K: Results of Operations and Financial Condition
Fourth quarter and full year 2025 total revenue of $192.6 million and $616.3 million, including BRIUMVI U.S. net revenue of $182.7 million and $594.1 million, respectively |
| 13 Jan 2026 |
8-K: Regulation FD Disclosure
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones |
| 03 Nov 2025 |
8-K: Results of Operations and Financial Condition
Third quarter 2025 total revenue of $161.7 million, including BRIUMVI U.S. net revenue of $152.9 million |
| 04 Aug 2025 |
8-K: Results of Operations and Financial Condition
Second quarter 2025 total revenue of $141.1 million, including BRIUMVI U.S. net revenue of $138.8 million |
| 13 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On Thursday, June 12, 2025, at 9:30 a.m. Eastern Time, by means of an online meeting platform, TG Therapeutics, Inc. (the “Company”) held its 2025 Annual Meeting. Stockholders representing 118,430,391, or 74.58%, of the 158,776,296 outst... |
| 05 May 2025 |
8-K: Results of Operations and Financial Condition
First quarter 2025 BRIUMVI U.S. net revenue of $119.7 million |
| 03 Mar 2025 |
8-K: Results of Operations and Financial Condition
Fourth quarter and full year 2024 BRIUMVI U.S. net revenue of $103.6 million and $310 million, respectively |
| 14 Jan 2025 |
8-K: Regulation FD Disclosure
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue and 2025 Anticipated Development Milestones |
| 04 Nov 2024 |
8-K: Results of Operations and Financial Condition
TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance |
| 06 Aug 2024 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +2 more
TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance |
| 17 Jun 2024 |
8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
TG Therapeutics, Inc., a corporation organized and existing under and by virtue of the Delaware General Corporation Law (the “Corporation”), does hereby certify: |
| 01 May 2024 |
8-K: Results of Operations and Financial Condition
First quarter 2024 BRIUMVI U.S. net revenue of $50.5 million, representing >25% quarter over quarter growth |
| 28 Feb 2024 |
8-K: Results of Operations and Financial Condition
Fourth quarter and full year 2023 BRIUMVI U.S. net revenue of approximately $40 million and $89 million, respectively |
Loading...